ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 149 filers reported holding ASCENDIS PHARMA A/S in Q1 2020. The put-call ratio across all filers is 0.46 and the average weighting 0.8%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $69,762 | -17.5% | 745 | -21.4% | 0.00% | – |
Q2 2023 | $84,609 | -18.2% | 948 | -1.8% | 0.00% | – |
Q1 2023 | $103,467 | +134.0% | 965 | +166.6% | 0.00% | – |
Q4 2022 | $44,211 | -99.9% | 362 | -54.8% | 0.00% | – |
Q3 2022 | $82,608,000 | +22.6% | 800 | +10.3% | 0.00% | – |
Q2 2022 | $67,396,000 | -95.5% | 725 | -93.5% | 0.00% | -100.0% |
Q4 2021 | $1,505,525,000 | +10.5% | 11,191 | -7.5% | 0.00% | -33.3% |
Q1 2020 | $1,362,581,000 | – | 12,100 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RA Capital Management | 10,719,555 | $1,003,779,130 | 19.76% |
Q Global Advisors, LLC | 285,000 | $26,687 | 17.16% |
Finepoint Capital LP | 163,772 | $15,335,610 | 7.64% |
Avoro Capital Advisors LLC | 3,670,000 | $343,658,800 | 5.36% |
Spyglass Capital Management LLC | 614,618 | $57,552,830 | 4.51% |
Sofinnova Investments, Inc. | 754,032 | $70,607,556 | 4.45% |
Saturn V Capital Management LP | 112,473 | $10,531,972 | 4.41% |
DAFNA Capital Management LLC | 136,212 | $12,754,892 | 3.97% |
ARS Investment Partners, LLC | 285,918 | $26,773,362 | 3.32% |
Ghost Tree Capital, LLC | 85,000 | $7,959,400 | 2.62% |